Ant Group and rivals race to commercialise AI healthcare in China
China's AI healthcare financing jumped from RMB 3.7 billion ($552 million) — after two years of stagnation — to RMB 13.9 billion ($2.07 billion) in 2026, drawing Ant Group, JD Health, Tencent, and iFlytek into direct competition.
3 MIN READ · 16 OCT
Subscriber Content
Subscribe to read the full analysis
Subscribe to read everything on GATE86
Already a subscriber? Log in
Next in Today's signals
INDUSTRY · SEMICONDUCTORS
CXMT chip advance triggers KOSPI plunge and Asian tech selloff
3 MIN READ · 14 OCT
Related
INDUSTRY · AI & DIGITAL
Butterfly Effect raises over $500 million as Manus reclaims independence
INDUSTRY · ROBOTICS & AUTOMATION
Chinese embodied AI entrepreneurs debate path from lab to commercial deployment
INDUSTRY · AI & DIGITAL